> Roche ($RHHBY) is collaborating with the French Agency for Research on AIDS and viral hepatitis, the French National Research Institute, and the Baylor Research Institute for vaccines in AIDS, tuberculosis, and hepatitis C. Article
> Vaccine technology company TapImmune has licensed MHC Class I HER2/neu antigen technology from the Mayo Foundation for Education & Research; Dr. Glynn Wilson, chairman and CEO has described this as a "game changer." Press release | Article
> Following up on data in children, the University of Pittsburgh's glioma vaccine (now known as StemLine Therapeutic's SL-701) triggered immune responses in adults, with early hints of an effect against the cancer. Press release
> Intellect Neurosciences has signed an agreement to collaborate with the University California-Irvine to test Intellect's therapeutic and prophylactic Alzheimer's disease vaccine, RV03, in preclinical trials. Press release | Editor's Corner
> Australian startup Coridon has licensed a vector technology from Nature Technology Corp. for its herpes simplex virus Type 2 (HSV-2) DNA vaccine, currently in preclinical trials. Press release
> The University of Botswana, the Botswana Vaccine Institute, and the U.S. Pitzer University have signed an agreement to develop a number of infectious disease vaccines. Article
> Merck's ($MRK) supplies of Zostavax are being restored as manufacturing issues are sorted out. Article
And Finally… It must be awards season! At the 5th Vaccine Industry Excellence (ViE) Awards during the World Vaccine Congress Washington 2012, ImmunoVaccine was named as the "Best Early-Stage Vaccine Biotech" and Advaxis was selected as the "Best Therapeutic Vaccine (approved or in development)." ImmunoVaccine press release | Advaxis press release